US ISMP criticises PhRMA's call to eradicate FDA drug name reviews
This article was originally published in SRA
Executive Summary
The non-profit Institute for Safe Medication Practices (ISMP) has criticised a recommendation from pharmaceutical industry association PhRMA that the Food and Drug Administration's proprietary name-review process should be repealed until the agency can prove it is effective in reducing medication errors.